The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 27, 2017

Filed:

Jun. 19, 2015
Applicant:

Chungbuk National University Industry—academic Cooperation Foundation, Cheongju-si, KR;

Inventors:

Wun-Jae Kim, Cheongju-si, KR;

Seok-Joong Yun, Cheonju-si, KR;

Won-Tae Kim, Cheongju-si, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/574 (2006.01); C12N 15/113 (2010.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12N 15/113 (2013.01); G01N 33/57407 (2013.01); A61K 39/39533 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4727 (2013.01); G01N 2333/71 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to a method for predicting the probability of muscle-invasive bladder cancer (MIBC) recurrence or metastasis, a method for providing information on a personalized medicine of MIBC, and a pharmaceutical composition for treating MIBC, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients. According to the present invention, it is possible to accurately predict a prognosis after chemotherapy of an MIBC patient, to provide information on cisplatin sensitivity in the provision of a personalized medicine for chemotherapy of an MIBC patient, and to increase the cisplatin sensitivity of an MIBC patient by concomitantly administering S100A9 and EGFR inhibitors together with a conventional cisplatin.


Find Patent Forward Citations

Loading…